乳腺癌骨转移分子机制及靶向药物的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (3): 433-437.

乳腺癌骨转移分子机制及靶向药物的研究进展

郑亚男¹, 李梅^1,2, 赵基源^1*

1.宁波大学医学院浙江省病理生理学技术研究重点实验室,浙江宁波 315211;
2.宁波市医学科学研究所,浙江宁波 315211

收稿日期:2020-04-15 修回日期:2020-07-27 出版日期:2021-03-05 发布日期:2021-03-01
通讯作者: ^*zhaojiyuan@nbu.edu.cn
基金资助:
国家自然科学基金(31300800, 81702625);宁波市自然科学基金(2018A610202, 2019A610309)

Progress in molecular mechanism and targeted drugs of bone metastases in breast cancer

ZHENG Ya-nan¹, LI Mei^1,3, ZHAO Ji-yuan^1*

1. Zhejiang Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo 315211;
2. Ningbo Institute of Medical Sciences, Ningbo 315211, China

Received:2020-04-15 Revised:2020-07-27 Online:2021-03-05 Published:2021-03-01
Contact: ^*zhaojiyuan@nbu.edu.cn

摘要/Abstract

摘要： 乳腺癌是威胁全世界女性健康最常见的恶性肿瘤,骨是最容易发生转移的部位。乳腺癌骨转移的分子机制和靶向治疗药物已经成为当前研究的热点。本文归纳了参与调节乳腺癌骨转移的关键分子,并分别从靶向破骨细胞和成骨细胞两个类别对重要的靶向治疗药物进行介绍和疗效比较。

关键词: 乳腺癌骨转移, 恶性循环, 信号分子, 治疗靶点

Abstract: Breast cancer is the most common malignant tumor that threatens the health of women around the world, and bone is the site most prone to metastasis. The molecular mechanism concerned and targeted therapy against bone metastasis of breast cancer have become the current research hotspots. This article summarizes the key molecules involved in regulating bone metastasis of breast cancer. The important targeted therapy drugs are introduced and their efficacy is compared in two categories of those targeting at osteoclasts and those targeting at osteoblasts.

Key words: breast cancer bone metastasis, vicious cycle, signal molecule, therapeutic target

中图分类号:

R736.3

郑亚男, 李梅, 赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展[J]. 基础医学与临床, 2021, 41(3): 433-437.

ZHENG Ya-nan, LI Mei, ZHAO Ji-yuan. Progress in molecular mechanism and targeted drugs of bone metastases in breast cancer[J]. Basic & Clinical Medicine, 2021, 41(3): 433-437.

参考文献

[1] 马丹丹, 刘坤, 齐晓伟. 2018年全球癌症统计:乳腺癌发病和死亡人数统计[J]. 中华乳腺病杂志(电子版), 2018, 12:375-375.
[2] Romero-Moreno R, Curtis KJ, Coughlin TR, et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis[J]. Nat Commun, 2019, 10:1-14.
[3] Wu XQ, Li FF, Dang L, et al. RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies[J]. Front Cell Dev Biol, 2020, 8:1-14
[4] Calvano Küchler E, Maschietto Pucinelli C, Carpio Horta K, et al. Dental caries, developmental defects of enamel and enamel microhardness associated with genetic polymorphisms in the RANK/RANKL/OPG system[J]. J Clin Pediatr Dent, 2020, 44:35-40.
[5] Gu XY, Peng YY, Zhao YY, et al. A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer[J]. Eur J Pharmacol, 2019, 858:1-13.
[6] Liang Y, Yi L, Liu P, et al. CX3CL1 involves in breast cancer metastasizing to the spine via the Src/FAK signaling pathway[J]. J Cancer, 2018, 9:3603-3612.
[7] Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases[J]. Proc Natl Acad Sci USA, 2003, 100:10954-10959.
[8] Bendinelli P, Maroni P, Matteucci E, et al. Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer[J]. Biochim Biophys Acta, 2014, 1843:815-826.
[9] Sun JB, Huang JZ, Lan J, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer[J]. Cancer Cell Int, 2019, 19:1-11.
[10] Hsu YL, Hou MF, Kuo PL, et al. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/Snail signaling pathway[J]. Oncogene, 2012, 32:1-12.
[11] Wang L, Song LJ, Li J, et al. Bone sialoprotein-alpha v beta 3 integrin axis promotes breast cancer metastasis to the bone[J]. Cancer Sci, 2019, 110:3157-3172.
[12] Chou YT, Wang H, Chen Y, et al. CITED2 modulates TGF-beta-mediated upregulation of MMP9[J]. Oncogene, 2006, 25:5547-5560.
[13] Jayaraman S, Doucet M, Lau WM, et al. CITED2 modulates breast cancer metastatic ability through effects on IKK alpha[J]. Mol Cancer Res, 2016, 14:730-739.
[14] Coleman R, Powles T, Paterson A, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386:1353-1361.
[15] Sakaguchi K, Ono H, Nakatsukasa K, et al. Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer[J]. Medicine, 2019, 98:1-6.
[16] Zhang C, Zhang F, Liang G, et al. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years[J]. BMC Musculoskelet Disord, 2018, 19:1-9.
[17] Oruç Z, Kaplan MA, Arslan Ç. An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients[J]. Expert Opin Pharmacother, 2018, 19:1305-1316.
[18] Ma GT, Lee SK, Park KK, et al. Artemisinin-daumone hybrid inhibits cancer cell-mediated osteolysis by targeting cancer cells and osteoclasts[J]. Cell Physiol Biochem, 2018, 49:1460-1475.
[19] Paul D, Vukelja SJ, Ann Holmes F, et al. Randomized phase-Ⅱ evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients[J]. NPJ Breast Cancer, 2019, 5:1-7.
[20] De Felice M, Lambert D, Holen I, et al. Effects of Src-kinase inhibition in cancer-induced bone pain[J]. Mol Pain, 2016, 12:1-14.
[21] O'Carrigan B, Wong MHF, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer[J]. Cochrane Database Syst Rev, 2017, 10:1-172.
[22] Tesfamariam Y, Jakob T, Wöckel A, et al. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: a systematic review and network meta-analysis[J]. Crit Rev Oncol Hematol, 2019, 137:1-8.
[23] Cheng X, Tan S, Duan F, et al. Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM[J]. Breast Cancer, 2019, 26:766-775.
[24] Li M, Zhang C, Zhong Y, et al. A novel approach to utilize Icariin as Icariin-derived ECM on small intestinal submucosa scaffold for bone repair[J]. Ann Biomed Eng, 2017, 45:2673-2682.
[25] Li M, Zhang C, Li XH, et al. Isoquercitrin promotes the osteogenic differentiation of osteoblasts and BMSCs via the RUNX2 or BMP pathway[J]. Connect Tissue Res, 2019, 60:189-199.